首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression
【2h】

Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression

机译:急性和慢性慢性肝功能衰竭的人工和生物人工肝支持系统:荟萃分析和荟萃回归

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Artificial and bioartificial liver support systems (LSSs) appear to be safe and effective in the treatment of acute and acute-on-chronic hepatic failure (AHF and AOCHF); however, individually published studies and previous meta-analyses have revealed inconclusive results. The aim of the present meta-analysis was to derive a more precise estimation of the benefits and disadvantages of artificial and bioartificial LSSs for patients with AHF and AOCHF. A literature search was conducted in the PubMed, Embase, Web of Science and Chinese Biomedical (CBM) databases for publications prior to March 1, 2013. Crude relative risks (RRs) or standardized mean differences (SMDs) with 95% confidence intervals (95% CI) were calculated using either the fixed effects or random effects models. Nineteen randomized controlled trials (RCTs) were included, which comprised a total of 566 patients with AHF and 371 patients with AOCHF. The meta-analysis showed that artificial LSS therapy significantly reduced mortality in patients with AOCHF; however, it had no apparent effect on total mortality in patients with AHF. The results also indicated that the use of bioartificial LSSs was correlated with decreased mortality in patients with AHF. A significant reduction in the bridging to liver transplantation was observed in patients with AOCHF following artificial LSS therapy; however, similar results were not observed in patients with AHF. Patients with AHF and those with AOCHF showed significant reductions in total bilirubin levels following artificial LSS therapy. There were no significantly increased risks of hepatic encephalopathy or bleeding in either the patients with AHF or AOCHF following artificial or bioartificial LSS therapies. Univariate and multivariate meta-regression analyses confirmed that none of the factors explained the heterogeneity. The present meta-analysis indicated that artificial LSSs reduce mortality in patients with AOCHF, while the use of bioartificial LSSs was correlated with reduced mortality in patients with AHF.
机译:人工和生物人工肝支持系统(LSSs)在治疗急性和慢性肝功能衰竭(AHF和AOCHF)方面似乎是安全有效的。然而,单独发表的研究和以前的荟萃分析显示了不确定的结果。本荟萃分析的目的是对AHF和AOCHF患者使用人工和生物人工LSS的利弊进行更精确的估算。在PubMed,Embase,Web of Science和中国生物医学(CBM)数据库中进行了文献检索,以查找2013年3月1日之前的出版物。相对危险度(RRs)或标准化均值(SMD)的置信区间为95%(95使用固定效应或随机效应模型来计算%CI)。包括19个随机对照试验(RCT),其中包括566例AHF患者和371例AOCHF患者。荟萃分析显示,人工LSS治疗可显着降低AOCHF患者的死亡率。但是,它对AHF患者的总死亡率没有明显影响。结果还表明,使用生物人工LSS与AHF患者的死亡率降低相关。人工LSS治疗后AOCHF患者的肝移植桥接明显减少。然而,在AHF患者中未观察到类似结果。人工LSS治疗后,AHF和AOCHF患者的总胆红素水平显着降低。人工或生物人工LSS治疗后,AHF或AOCHF患者的肝性脑病或出血​​风险均没有显着增加。单变量和多元元回归分析证实,没有任何因素可以解释异质性。目前的荟萃分析表明,人工LSS可降低AOCHF患者的死亡率,而生物人工LSS的使用与AHFHF患者的死亡率降低相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号